Shalby Hospitals' Krishna Unit Receives 5-Year Approval for Kidney Transplants

Shalby Limited (NSE: SHALBY / BSE: 540797), a leading multi-specialty hospital chain, has announced a significant expansion of its clinical services. The company's Krishna Unit in Ahmedabad, Gujarat, has officially received regulatory approval to perform Kidney Transplants.

The license is valid for a period of five years, effective from April 9, 2026. This milestone marks a major step forward for the facility, transitioning it into a specialized center for advanced renal care.

Enhancing Patient Care and Accessibility

The introduction of transplant services at the Krishna Unit is expected to provide several key benefits to the local community:

Localized Access: Patients in Ahmedabad and surrounding regions can now access life-saving transplant surgeries without the burden of long-distance travel.

Comprehensive Care: The hospital will offer a full spectrum of services, including pre-transplant evaluation and intensive post-transplant management, all under one roof.

Reduced Costs: Localized treatment is expected to lower the overall financial burden on families by reducing associated travel and accommodation expenses.

Shares of Shalby Limited was last trading in BSE at Rs. 153.55 as compared to the previous close of Rs. 151.00. The total number of shares traded during the day was 21074 in over 564 trades.

The stock hit an intraday high of Rs. 158.20 and intraday low of 152.30. The net turnover during the day was Rs. 3263918.00.

Source : Equity Bulls

Keywords

Shalby INE597J01018 HealthcareFacilities KrishnaUnit Approval KidneyTransplants